tirzepatide isn't working anymore a weight drug. It's an inflammation drug that happens to help with weight. That's why it's quietly changing the MCAS conversation. Dual GLP-1 / GIP agonist. GLP-1 slows gut motility For those saying Tirzepatide is

In the SURPASS-2 trial, which directly compared tirzepatide to semaglutide 1 mg for type 2 diabetes, nausea rates were 17-22% for tirzepatide across all three dose levels (5 mg, 10 mg, and 15 mg) versus 18% for semaglutide 1 mg

Patients with longstanding type 2 diabetes often have substantial beta-cell loss, which can vary among individuals, potentially limiting their capacity to increase insulin secretion even with dual GIP/GLP-1 receptor stimulation

However, if a particular site consistently causes significant discomfort or reactions, discuss alternative sites with your healthcare provider

At the same time, symptoms affecting the skin can sometimes be dermatological reactions , meaning reactions involving the skin itself

Certain tirzepatide compound formulations can cause more injection site irritation than others

Always swab the top with alcohol before each draw